Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1

ValiRx Plc - Bioscience Innovation (VAL)     

Robbie C - 12 May 2013 13:01



Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that enhance patient care, achieve faster diagnoses, and substantially improve treatment outcomes cost effectively.

Valirx is a growing company with a clear business model. We reduce risk in new product development through a rigorous clinical and commercial due diligence process, selecting drug candidates and technologies with evidence-based potential to address the unmet needs of the market. We aim to maximise returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Valirx management team is a mixture of entrepreneurial scientists and business professionals, all with experience in developing medical life science companies. The team is also experienced at transferring technologies and products into the commercial arena to generate revenue and grow shareholder value.

Latest News - http://www.valirx.com/news

Bullshare - 17 Jan 2018 10:03 - 18 of 20

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London. Directors from London Stock Exchange listed companies will present their latest plans regarding development and growth, you will have also have the opportunity to talk directly to the Directors and put forward your questions.
 
 
PrimaryBid - PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions.  To date almost £37m has been sourced for issuers, via the platform.
 
 
Rockhopper Exploration (RKH) - Rockhopper is an AIM listed oil and gas company based in the UK with interests in the Falkland Islands and the Greater Mediterranean region. Rockhopper’s strategy is to build a well-funded, full-cycle, exploration led E&P company.
 
The Company is the leading acreage holder in the North Falkland Basin with independently audited 2C oil resources, net to Rockhopper, in excess of 250 mmbbl.
 
Through a series of acquisition and organic growth initiatives, Rockhopper has built a portfolio of production and exploration assets in the Greater Mediterranean which produced approximately 1,350 boepd during 2016 and is expected to generate material future exploration activity.
 
 
Valirx (VAL) - Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.
 
Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.
 
The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.
Who Should Attend?

The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy. 

Date:

Tuesday 13 February 2018

Venue:

Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Dave Mutton, Chief Operating Officer - PrimaryBid
• Stewart MacDonald, CFO - Rockhopper Exploration (RKH)
• Dr. Satu Vainikka, CEO - Valirx (VAL)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
PrimaryBid
PrimaryBid 

PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions.  To date almost £37m has been sourced for issuers, via the platform.

Rockhopper Exploration (RKH)
Rockhopper Exploration (RKH) 

Rockhopper Exploration plc ("Rockhopper") is an AIM listed oil and gas exploration company based in the UK with interests in the Falkland Islands.  It was established in 2004 with a strategy to invest in and undertake an offshore oil exploration programme.  It was floated on AIM in August 2005.

Rockhopper holds 40% interests in production licences PL032 and PL033 and, on completion of a farm-in announced in October 2013, 24% stakes in blocks PL004a, PL004b, and PL004c. All of these blocks are operated by Premier Oil. In addition, it has a 3% interest block PL003, operated by Falkland Oil and Gas.

In August 2014 Rockhopper completed the takeover of Mediterranean Oil & Gas plc ("MOG"). Through the acquisition of MOG, Rockhopper now holds a portfolio of production, development/appraisal and exploration interests in Italy, Malta and France.

Valirx (VAL)
Valirx (VAL) 

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Sponsored by:
AJ Bell Youinvest
PrimaryBid

black bird - 06 Feb 2018 12:00 - 19 of 20

val avoid until large holder buys, Jarvis unloading at present, will buy @ 2p BB
ps is rights , more money wanted.

mitzy - 07 Feb 2018 12:30 - 20 of 20

Chart.aspx?Provider=EODIntra&Code=VAL&Si
  • Page:
  • 1
Register now or login to post to this thread.